Optomed Plc Inside Information 11 November 2020 at 9.30,
Helsinki
Optomed has received a regulatory approval for Optomed Aurora in China
Optomed has received a medical devices regulatory approval in the People’s
Republic of China for Optomed’s latest generation handheld camera, Optomed
Aurora.
The Chinese Food and Drug Administration (CFDA) approval allows Optomed to start
commercial operations of Optomed Aurora in the People’s Republic of China. Prior
to this approval, Optomed has only been able to sell its previous generation
camera, Smartscope Pro, in China.
Optomed Aurora is made for examination and documentation of the retina for
various eye diseases and neurological disorders. The Aurora camera is non
-mydriatic, which means there is no need for pupil dilatation when imaging the
fundus. It has a 50-degree field-of-view which is useful especially in diabetic
retinopathy screening. The Aurora camera can be easily integrated into different
hospital systems.
Laura Piila, Optomed’s Vice President Devices comments: “First, I would like to
thank everybody involved with the approval process. The approval enables us to
provide a camera that represents our latest technology to our Chinese customers
which again helps to prevent avoidable blindness and reduce overall healthcare
costs in China. All internal launch preparations are completed, so sales
activities can start immediately”.
Optomed Plc
Further enquiries
Seppo Kopsala, CEO, Optomed Plc, seppo.kopsala@optomed.com
Laura Piila, Vice President Devices, Optomed Plc, +358 40 588 1187,
laura.piila@optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye-screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries. The
company has an extensive portfolio of 55 international patents protecting the
technology. In 2019, Optomed’s revenue reached EUR 15 million and at the end of
2019 Optomed employed 108 professionals.